Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group.
Open Access
- 1 July 1994
- Vol. 49 (7) , 652-656
- https://doi.org/10.1136/thx.49.7.652
Abstract
BACKGROUND--Recent reports have suggested short-term changes in serum parameters of bone metabolism with inhaled corticosteroids. The relevance of these findings to the balance between bone formation and resorption during years of corticosteroid treatment remains uncertain. METHODS--Two novel markers of bone turnover were first compared with conventional markers in a pilot study and subsequently measured in a long-term double blind study of inhaled corticosteroids. In study I 15 patients were newly started on at least 800 micrograms inhaled corticosteroids daily. At entry and after four weeks serum levels of alkaline phosphatase, osteocalcin, and PICP (procollagen type I carboxy terminal propeptide; a procollagen splice product) were measured as markers of bone formation, as well as the urinary hydroxyproline/creatinine ratio and serum levels of ICTP (type I collagen carboxy terminal telopeptide; a collagen degradation product) as markers of bone resorption. In study II 70 patients with airways obstruction received 800 micrograms beclomethasone daily in addition to terbutaline and 85 received bronchodilators only in a double blind fashion. Serum levels of PICP and ICTP were measured before and after 2.5 years of treatment. RESULTS--In study I a decrease in osteocalcin levels was accompanied by an increase in levels of PICP and a small and non-significant rise in alkaline phosphatase. There were no changes in hydroxyproline or ICTP. In study II no differences were found in serum levels of PICP between the treatment groups; an increase in serum ICTP was found in the group treated without inhaled corticosteroids compared with the group treated with inhaled corticosteroids. CONCLUSIONS--No detrimental long-term effect of inhaled corticosteroids was found with three conventional and two novel parameters of bone metabolism. The results indicate that long-term changes in bone turnover during treatment with inhaled corticosteroids should not be deduced from short-term studies with single serum parameters of bone metabolism, but well designed long-term studies of, for example, bone densitometry should be awaited before quoting detrimental effects of inhaled corticosteroids on bone metabolism.Keywords
This publication has 26 references indexed in Scilit:
- Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometryJournal of Bone and Mineral Research, 1993
- Effects of dose and dosing schedule of inhaled budesonide on bone turnoverJournal of Allergy and Clinical Immunology, 1991
- Growth of asthmatic children during treatment with budesonide: a double blind trial.BMJ, 1991
- Beclomethasone inhalation decreases serum osteocalcin concentrations.BMJ, 1991
- Bone turnover during high dose inhaled corticosteroid treatment.Thorax, 1991
- Osteocalcin: Diagnostic Methods and Clinical ApplicationsCritical Reviews in Clinical Laboratory Sciences, 1991
- Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphataseJournal of Bone and Mineral Research, 1987
- Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implantsCell Differentiation, 1987
- Multiple immunoreactive forms of osteocalcin in uremic serum.Journal of Clinical Investigation, 1986
- Resorption of implanted bone prepared from normal and warfarin-treated rats.Journal of Clinical Investigation, 1984